Clinical trials: Cancer of the Cervix
EGFR Overexpression, Locally Advanced Solid Tumor
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can…
- Conditions
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT06975410
- Testing
- YH32364
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yuhan Corporation
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Urothelial Carcinoma, Cholangiocarcinoma
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with advanced urothelial carcinoma, cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree and squamous cell carcinoma of…
- Conditions
- Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- iNSITE2 (NCT02479178)
- Testing
- BIND-014 (docetaxel nanoparticles for injectable suspension)
- Where
- 23 sites in United States, Russia
- Volunteers
- 73 people
- Sponsor
- BIND Therapeutics
Cervical Cancer
Clinical Trial for Registration of HPV Nucleic Acid Genotyping Assay Kit
The objective of this study is to verify the clinical effectiveness of HPV Genotyping Nucleic Acid Assay Kit. This is a multi-center clinical study involving at least three study centers, each with screening sites.
- Trial name
- NCT04461678
- Testing
- HPV Genotyping Nucleic Acid Assay Kit
- Where
- 5 sites in China
- Volunteers
- 12,230 people
- Sponsor
- Becton, Dickinson and Company
Papillomavirus Infections
A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).
This study will evaluate the safety, tolerability, and immunogenicity of V503 in Japanese girls between the ages of 9 and 15 and will determine whether V503 induces an acceptable immune response to all human papillomavirus (HPV)…
- Trial name
- NCT01254643
- Testing
- V503
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
This study is intended to provide up to a maximum of four years of annual oncogenic human papillomavirus (HPV) DNA testing and cervical cytology examination for NCT00294047 study subjects who displayed normal cervical cytology…
- Trial name
- NCT01190176
- Testing
- Gynaecological follow-up, Cervarix
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. This study is designed to evaluate the long-term immunogenicity and safety of the GSK Biologicals' 580299 HPV…
- Trial name
- NCT00947115
- Testing
- Blood sampling, Cervico-vaginal secretion (CVS) samples
- Where
- 6 sites in Germany, Poland
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Ovarian Cancer, Clear Cell Carcinoma
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
- Conditions
- Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma
- Trial name
- NCT05032040
- Testing
- vudalimab
- Where
- 17 sites in United States
- Volunteers
- 170 people
- Sponsor
- Xencor, Inc.
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Phase II study: a study to explore the safety and preliminary efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab Phase III study: a confirmatory study to evaluate the safety and efficacy of BAT1308…
- Trial name
- NCT06123884
- Testing
- Recombinant humanized anti-PD-1 monoclonal antibody injection, Cisplatin, Bevacizumab Injection
- Where
- China
- Volunteers
- 526 people
- Sponsor
- Bio-Thera Solutions
Cervical Cancer, Ovarian Cancer
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic cervical cancer or ovarian cancer failed or…
- Trial name
- NCT06769152
- Testing
- HLX43
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Shanghai Henlius Biotech
HPV Infection, HPV-Related Cervical Carcinoma
Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
A total of 480 Chinese women aged 18-26 years old were enrolle，experimental group and the control group were randomly assigned in a ratio of 3:1. 360 Chinese women in the experimental group and 120 in the control group.
- Trial name
- NCT04436133
- Testing
- Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha), 9-valent HPV vaccine（Gardasil 9）
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Infections, Papillomavirus
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
Genital infections with oncogenic human papillomaviruses (HPV) are common in both men and women. The most important disease associated with oncogenic HPV infection is cervical cancer, currently the second leading cause of…
- Trial name
- NCT00534638
- Testing
- Cervarix, Engerix-B
- Where
- 6 sites in Finland
- Volunteers
- 34,412 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Cervical Cancer
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer.
- Trial name
- NCT03786081
- Testing
- Tisotumab Vedotin, Bevacizumab, Pembrolizumab
- Where
- 71 sites in United States, Belgium and 8 more
- Volunteers
- 214 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Cervical Cancer, Genital Warts
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
The primary purpose of the study is to determine if an investigational vaccine Gardasil (V501) with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.
- Trial name
- NCT00092495
- Testing
- V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 3,055 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Cervical Intraepithelial Neoplasia II
Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer
The purpose of this study is to determine whether Insulin-like Growth Factor II is elevated sufficiently to detect Cervical Intraepithelial Neoplasia II (CIN II), Cervical Intraepithelial Neoplasia III (CIN III), and cervical…
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia II, Cervical Intraepithelial Neoplasia III
- Trial name
- NCT01371695
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Onconix, Inc
Endometrial Cancer, Ovarian Cancer
Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
The purpose of Part 1 (Phase 1b) is to evaluate the general safety and tolerability of repeated 21-day cycles of AL3818 therapy, and to reevaluate the maximum tolerated dose (MTD).
- Conditions
- Endometrial Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- AL3818 (NCT02558348)
- Testing
- AL3818
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Advenchen Laboratories, LLC